Guizhou Xinbang Pharmaceutical Co., Ltd.

SZSE:002390.SZ

4.56 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 6,433.4156,350.0266,471.8665,845.6226,655.0646,580.2796,002.4715,157.0324,179.7562,476.183569.488447.572361.865318.628336.686274.743217.754173.328
Cost of Revenue 5,340.9245,133.0655,119.3714,593.5445,190.5495,146.7484,745.8624,048.8413,318.6221,837.85213.936166.983128.706111.226103.40485.38876.63560.738
Gross Profit 1,092.4911,216.961,352.4961,252.0781,464.5151,433.5311,256.6091,108.19861.135638.333355.552280.59233.159207.402233.282189.355141.118112.59
Gross Profit Ratio 0.170.1920.2090.2140.220.2180.2090.2150.2060.2580.6240.6270.6440.6510.6930.6890.6480.65
Reseach & Development Expenses 4.6391.2071.93810.56336.57836.69230.17525.3936.9445.0097.3016.0292.78500000
General & Administrative Expenses 118.548149.917127.188124.15149.476156.709103.88883.54177.28736.7632.42420.43716.12734.60827.02223.90715.52814.155
Selling & Marketing Expenses 343.414393.368360.194399.102432.25424.236366.863384.148307.806272.043248.514194.27156.779130.514140.235120.84785.87169.745
SG&A 682.341543.285487.381523.252581.726580.945470.751467.689385.093308.803280.938214.707172.905165.122167.257144.755101.39983.9
Other Expenses -7.323291.956297.829268.306325.425-16.046-3.28484.53644.0624.20710.29411.553-3.4224.220.9355.6936.2650.316
Operating Expenses 694.303836.448787.148802.121943.729929.11730.392712.217555.444397.46307.76232.437190.466168.962170.942147.556103.63685.755
Operating Income 398.188427.818451.51429.906526.567-1,195.362422.416231.184184.412175.05137.48745.8748.59538.91853.25532.91928.07521.156
Operating Income Ratio 0.0620.0670.070.0740.079-0.1820.070.0450.0440.0710.0660.1020.1340.1220.1580.120.1290.122
Total Other Income Expenses Net -2.167-114.425-30.385-162.45-195.09-1,715.829-107.085-83.962-77.491-41.837-0.019.2110.8365.705-8.151-3.215-3.068-5.381
Income Before Tax 396.022313.394421.125267.456331.477-1,211.408419.132312.012228.2199.03647.78257.36353.52844.14554.1938.58434.41421.455
Income Before Tax Ratio 0.0620.0490.0650.0460.05-0.1840.070.0610.0550.080.0840.1280.1480.1390.1610.140.1580.124
Income Tax Expense 42.24944.97747.1746.88167.75671.77587.64569.30859.7945.1798.1069.87.6526.5627.7734.974.5034.641
Net Income 287.233224.374373.955173.521236.302-1,296.605319.384246.013174.379144.7740.23747.82946.07937.75746.41633.61429.91117.451
Net Income Ratio 0.0450.0350.0580.030.036-0.1970.0530.0480.0420.0580.0710.1070.1270.1190.1380.1220.1370.101
EPS 0.150.120.210.110.15-0.80.190.150.140.130.0480.0560.0540.0480.0720.0520.0460.027
EPS Diluted 0.150.120.210.110.15-0.80.190.150.140.130.0480.0560.0540.0480.0720.0520.0460.027
EBITDA 654.015671.365799.239661.553764.952730.957714.844669.912494.416329.83985.16879.20470.23155.57271.6555.38644.52728.352
EBITDA Ratio 0.1020.1060.1230.1130.1150.1110.1190.130.1180.1330.150.1770.1940.1740.2130.2020.2040.164